Non-alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified
Conditions
Interventions
Intervention 1: control group: Vitamin E400, 1 capsule/day for one month. Intervention 2: Intervention Group: injection of vitamin D at the dose of 600000 IU at the beginning of study and Vitamin E4
Treatment - Drugs
control group: Vitamin E400, 1 capsule/day for one month
Intervention Group: injection of vitamin D at the dose of 600000 IU at the beginning of study and Vitamin E400, 1 capsule/day for one month
Sponsors
Vice Chancellor for research of Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: willingness to participate in the study, 18-50 years old, liver steatosis on sonographic image, vitamin D deficiency(25(OH)D levels less than 30ng/ml), BMI=25 Exclusion criteria: Alcohol consumption(more than 20g/day), menopause, gestation or lactation, BMI>40, diabetes and insulin resistance, any other liver disease(viral disease, Wilson, Hemochromatosis, glycogen storage disorders and etc) or using drugs for the treatment of fatty liver(such as omega-3 and herbal supplements), Thyroid and parathyroid disorders, bone problems, Cushing's syndrome, fat malabsorption, cholecystectomy and any other disease that affect the liver, renal disease(renal failure and nephrolithiasis), using vitamin D, calcium and vitamin E supplements in the past 6 months, taking any drugs causing fatty liver or hepatotoxic drugs(calcium channel blocker,methotrexate,tamoxifen, valproate, diltiazem, amiodarone, isoniazid, corticosteroids and high-dose of estrogen and progestin, and the use of contraceptives), taking drugs affecting insulin resistance and liver function(Such as metformin, pioglitazone, lovastatin and etc.), get weight loss diet in the past 6 months, using total parenteral nutrition in the past 6 months.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum 25(OH)D. Timepoint: Beginning and end of the intervention. Method of measurement: ELIZA.;Serum Adiponectin. Timepoint: Beginning and end of the intervention. Method of measurement: ELIZA.;Liver Enzyme (ALT,AST,ALP). Timepoint: Beginning and end of the intervention. Method of measurement: IFCC.;Liver steatosis. Timepoint: Beginning and end of the intervention. Method of measurement: Liver Sonography. | — |
Secondary
| Measure | Time frame |
|---|---|
| Anthropometry. Timepoint: Begining and end of intervention. Method of measurement: Scale and meter and bioelectrical impedance analyzer.;Energy and nutrient intake. Timepoint: Beginning and end of the intervention. Method of measurement: 24- hour dietary recall.;Physical activity. Timepoint: Begining and end of intervention. Method of measurement: Physical activity Questionnaire.;Sun exposure. Timepoint: Begining and end of intervention. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mehrangiz Ebrahimimamagani
Nutrition Faculty, Tabriz University of Medical Sciences
Outcome results
None listed